AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on December 22, 2022. The report addresses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate event and does not contain financial statements.
Material Changes
On December 22, 2022, Gary Cantrell, a member of the Board of Directors, notified the Company of his intention to retire, effective December 31, 2022. Mr. Cantrell stated there was no disagreement with the Company regarding operations, policies, or practices. The Company has initiated a search for an additional Board member.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, outlook, risks, contingencies, or unusual items beyond the director departure.
Key Facts for Investors
- Director Gary Cantrell is retiring effective December 31, 2022.
- The departure is not due to any disagreement with the Company.
- A search for a new Board member has commenced.
- No financial data is disclosed in this specific filing.